Gilead to buy cancer drug developer Arcellx for up to $7.8bn
Deal comes as pharmaceutical groups rush to acquire smaller biotech firms with proven drug pipelines
Related reading
Gilead nears up to $2bn deal for autoimmune biotech Ouro Medicines
California-based drugmaker takes advantage of surging share price to strike takeovers after a quiet couple of years
Novartis weighs deal for biotech Avidity to boost drug pipeline
Shares in rare disease biotech surge 26% following approach by Swiss group
How GSK is rebuilding its cancer business
A decade after exiting oncology, the UK pharma group is betting that R&D and acquisitions will help it hit sales of £40bn
Merck splits operations to separate oncology from non-cancer drugs
Reshuffle in preparation for 2028 US patent expiry of blockbuster cancer treatment Keytruda
Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion
Gilead Sciences said on Monday it will buy cancer therapy partner Arcellx for an implied equity value of $7.8 billion.
UK biotech keeps selling itself to America
A shortage of late-stage capital pushes the biggest prizes into US hands